Dietary supplement

PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules

Retrieved on: 
Wednesday, November 15, 2023
Capsule, Interest, Health Canada, Research, CSE, GMP, OTCQB, Entrepreneurship, MDMA, Clinical trial, NEO, Patient, FH, Batch, Monash University, MDXX, Filament, Partnership, PTSD, Pharmaceutical industry, Dietary supplement

VANCOUVER, British Columbia, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA)(OTCQB:PMBHF), a Canadian biotechnology company dedicated to the research and development of clinical-grade LaNeo™ MDMA and novel MDXX compounds, and Filament Health Corp. ( OTCQB:FLHLF ) ( NEO:FH ) ( FSE:7QS ) (“Filament”), a clinical-stage natural psychedelic drug development company, today announced the GMP release of a second batch of MDMA capsules encapsulated at Filament’s Metro Vancouver facility.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA)(OTCQB:PMBHF), a Canadian biotechnology company dedicated to the research and development of clinical-grade LaNeo™ MDMA and novel MDXX compounds, and Filament Health Corp. ( OTCQB:FLHLF ) ( NEO:FH ) ( FSE:7QS ) (“Filament”), a clinical-stage natural psychedelic drug development company, today announced the GMP release of a second batch of MDMA capsules encapsulated at Filament’s Metro Vancouver facility.
  • “With a number of regulatory changes over the past 6 months, we are pleased to have seen strong demand for our LaNeo MDMA Capsules,” said Nick Kadysh, CEO at PharmAla Biotech.
  • “With this second released batch, we’ve been incredibly proud to continue our work with the team at Filament to execute manufacture of our second batch of capsules.
  • “There is significant demand for GMP MDMA drug product and we are proud to meet that need with our industry-leading manufacturing capabilities,” said Benjamin Lightburn, CEO and Co-Founder of Filament Health.

Orion Research Foundation grants EUR 1,112,000 for research in 2024

Retrieved on: 
Wednesday, November 15, 2023
Helena Lewyn, Insulin resistance, Chemistry, Senior, DNA, Phenotype, Osteoarthritis, Patient, Pharmacy, Infection, Biology, National Institutes of Health, Seminal vesicles, Mitochondrion, Doctor of Philosophy, Veterinary medicine, Stem cell, Bangladesh Technical Education Board, Inflammation, Birgitta, Synovial fluid, Prevalence, Prenatal development, Carcinoma, Functional, Alzheimer's disease, Orion Corporation, Pancreatic serous cystadenoma, Ageing, Adipose tissue, Medicine, Sensitive, Physics, Pathology, FT, CALR, Colitis, Drug resistance, Oklahoma Medical Research Foundation, ELT, Obesity, Research, Trial of the century, EUR, Cystoscopy, Chronic lymphocytic leukemia, BMI, Turku University Hospital, Horse, Neoplasm, CLL, Pharmaceutical industry, Medical imaging, Dietary supplement, Vaccine

Orion Research Foundation sr is distributing EUR 1,112,000 in research grants based on applications for 2024.

Key Points: 
  • Orion Research Foundation sr is distributing EUR 1,112,000 in research grants based on applications for 2024.
  • Orion Reaserch Foundation awards grants of max EUR 50,000 for 17 researchers for postdoctoral research and max EUR 6,000 for 95 young researchers for doctoral dissertation work.
  • One of the postdoctoral grants was distributed from Maritza and Reino Salonen’s Fund which is administered by Orion Research Foundation.
  • Orion Research Foundation sr is annually distributing its return on investment and donations from Orion Corporation as grants for young researchers for doctoral dissertation work and postdoctoral research.

SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Tuesday, November 14, 2023
Chronic kidney disease, Neutrophil, Acute respiratory distress syndrome, STEC-HUS, Cardiorenal syndrome, Safety, Food, Hepatorenal syndrome, University, AKI, HDE, Risk, ICU, Clinical trial, Monocyte, Mortality, CBER, Sepsis, Patient, Nephrology, Insurance, Research, Letter, Dialysis, Approvable letter, FDA, G&A, Child, Standard of care, Acute kidney injury, Partnership, Nephron, Clinical study design, R, Hospital, SCD, Physician, CKRT, Karger Publishers, PMA, HIV disease progression rates, Pharmaceutical industry, Nursing, Dietary supplement, Cryptocurrency

DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

Key Points: 
  • DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2023 and provides a business update.
  • “Recent clinical and regulatory successes have significantly improved and strengthened our company’s prospects,” said Eric Schlorff, SeaStar Medical CEO.
  • SeaStar Medical expects regulatory approval for the SCD-ADULT in the first half of 2025 and commercial launch in the second half of 2025.
  • The Company issued two convertible notes each for $0.5 million in August 2023 and a third convertible note for $0.5 million in September 2023.

Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 14, 2023
Trigger, Annual general meeting, Chemistry, Patient, Small RNA, Exosome, PLOS, Kidney, Webcast, Therapy, Exon, Business, MUSCULAR, Employment, Food, International, PUL, LVEF, RRM2, Ovarian cancer, Duchenne muscular dystrophy, MRI, Horizon, Commercialization, Amgen, WMS, ID, AAEV, BLA, Cohort, Vaccine, Tissue, Distribution deal, PPMD, Asos, Partnership, Biologics license application, DMD, Apoptosis, Distribution, Liver, Protein, Biotechnology, Cohort study, Mouse, Poster, Omicron, FDA, Seminal vesicles, File, CMC, HIV disease progression rates, Dietary supplement, Mobile phone, Pharmaceutical industry, Fine chemical, Video game, Nursing

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Next steps for Cohort A:
    Plan to report the outcome from the interim futility analysis in the fourth quarter of 2023.
  • Held a positive Type-B clinical meeting with FDA in the third quarter of 2023.
  • Next steps for Cohort B:
    Expect to commence enrollment for Cohort B in the fourth quarter of 2023.
  • Revenues for the third quarter of 2023 were approximately $6.2 million compared with approximately $1.6 million for the third quarter of 2022.

Yield10 Bioscience Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Webcast, EPA, Genetics, Research, Aquaculture, Michigan State University, Biofuel, Farmer, Grain, Rothamsted, Rothamsted Research, Conference, DHA, Partnership, DOE, Letter, Government, MSU, Dietary supplement, Agriculture, Cryptocurrency, Camelina, Yield10 Bioscience

WOBURN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • -Exercises Option to Finalize Exclusive, Global Commercial License to Advanced Omega-3 Technology
    WOBURN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the three and nine months ended September 30, 2023.
  • Net cash used by operating activities during the third quarter of 2023 was $2.6 million compared to $2.7 million used in the third quarter of 2022.
  • Yield10 reported a net loss of $3.7 million for the quarter ended September 30, 2023, or $0.41 per share, as compared to a net loss of $3.5 million, or $0.71 per share, for the quarter ended September 30, 2022.
  • Yield10 Bioscience management will host a conference call today at 4:30 p.m. (ET) to discuss the third quarter 2023 results.

Know how to manage and prevent diabetes for a better life

Retrieved on: 
Tuesday, November 14, 2023
Well, Consensus, Chinese, World Diabetes Day, EASD, Consensus decision-making, Food, Chapter, Risk, American Diabetes Association, IDF, Patient, To Brazil!, ANAD, Sugar, WDD, Social media, Friends, International Diabetes Federation, Person, ISA, Family, Quality of life, Dietary supplement, Soft drink, Nutrition, Diabetes

Knowing your risk of type 2 diabetes to help delay or prevent the condition is important.

Key Points: 
  • Knowing your risk of type 2 diabetes to help delay or prevent the condition is important.
  • Alongside other cornerstones of diabetes management, a healthy diet has the potential to improve glucose control, reduce the risk of diabetes complications and improve quality of life.
  • More information about World Diabetes Day 2023 is available on the WDD website available at: https://worlddiabetesday.org
    IDF, Diabetes Atlas 10th edition 2021.
  • Consenso de la Asociación Latinoamericana de Diabetes sobre uso de edulcorantes no calóricos en personas con diabetes [Consensus of the Latin-American Association of Diabetes on low calorie sweeteners in persons with diabetes].

Else Nutrition Reports Third Quarter 2023 Financial Results and Provides Fourth Quarter Outlook

Retrieved on: 
Tuesday, November 14, 2023
Giant, Institutional review board, Interest, Infant, Safety, IRB, Bank statement, Supermarket, Risk, CAD, FDA, Danone, The Giant Company, Eastern Time Zone, SEDAR, MD, Trial of the century, Geography, Loblaws, CVS, Growth, Parent, Shoppers Drug Mart, Walmart, BABY, Video game, Rare-earth element, Retail, Online shopping, Grocery store, Renewable energy, Dietary supplement, Pharmaceutical industry, Amazon

VANCOUVER, British Columbia, Nov. 14, 2023 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC (BABY) (BABYF) (0YL.F) ("Else" or the "Company") the Plant-Based baby, toddler, and children nutrition company, today reported its third quarter 2023 financial results for the period ending September 30, 2023. The financial statements and MD&A are available on SEDAR under the Company’s profile.

Key Points: 
  • Revenue outlook in the range of $2.7 million to $3.0 million for the fourth quarter of 2023, representing growth of 58-75% compared to the third quarter of 2023.
  • Sales to brick-and-mortar retailers in the US and Canada during the third quarter increased by 8%, compared to the third quarter of 2022.
  • Cash position as of September 30, 2023, was $4.2 million CAD, including restricted cash and short-term bank deposits.
  • The Company will host a conference call to discuss the quarter's financial results today at 10:00 a.m. Eastern Time.

SOTERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Sotera Health Co. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, November 14, 2023
NATA, EPA, Pressure, Safety, Telephone, Poison, Offerings, Warburg Pincus, Risk, Probability, Culture, Agency, SPO, Goldman Sachs, JPMorgan Chase, Class, Health, Human services, SHC, School, IPO, Sterilization, Cancer, Human, Atmosphere, P.C, Ethylene oxide, Knowledge, GTCR, News, Cryptocurrency, Dietary supplement, Environmental remediation, Tobacco, Sotera Tschetter, Nordion

Our investigation concerns whether the board of directors of Sotera have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Sotera have breached their fiduciary duties to the company.
  • Sotera provides sterilization and lab testing and advisory services to the medical device and pharmaceutical industries.
  • The Company’s sterilization services rely on three primary technologies, one of which is Ethylene Oxide (“EtO”) processing.
  • Sotera, through its Sterigenics business, conducts or has conducted EtO processing at facilities located in Illinois, California, Georgia, and New Mexico.

PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

Retrieved on: 
Tuesday, November 14, 2023
Webcast, Research, POC, European Medicines Agency, Lysin, Therapy, Infection, Conference call, Bank statement, S. aureus, Escherichia coli, S, Risk, Mortality, Phage therapy, EMA, ANSM, Patient, CET, AAC, FDA, Klebsiella pneumoniae, Fungal infection, Health, Pseudomonas aeruginosa, Partnership, CMC, IVD, EI, Cryptocurrency, Pharmaceutical industry, Dietary supplement, Medical device, Vaccine, Conference, Bloodstream infections

The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.

Key Points: 
  • The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.
  • Key financial figures for the first nine months of 2023 compared with the same period of the previous year are summarized below.
  • In the context of the Erytech-Pherecydes merger, PHAXIAM’s consolidated financial statements in IFRS standards include ex-Pherecydes financial results as from the date of the merger, i.e.
  • Consequently, PHAXIAM’s P&L information for the first 9 months of 2023 include 9 months of ex-Erytech activities and ex-Pherecydes activities since June 23, 2023.

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

Retrieved on: 
Monday, November 13, 2023
Hepatology, Hyaluronic acid, Safety, Conditional sentence, ACE, ALT, AASLD, Physician, Disease, Risk, Artificial intelligence, Clinical trial, Liver disease, Cirrhosis, KPA, Collagen, Liver, TIMP1, HEPA, Fibrosis, Drug, Doctor of Philosophy, MASH, Patient, ELF, F4, Medical imaging, Pharmaceutical industry, Dietary supplement, F3

EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”; previously referred to as “NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced additional efficacy data for rencofilstat, its lead drug candidate.

Key Points: 
  • Dr. Mayo’s presentation indicated that 17 weeks of rencofilstat treatment was associated with significant reduction in liver stiffness (FibroScan®) in MASH subjects with advanced F3, an outcome suggesting reduction in hepatic fibro-inflammation.
  • Ongoing hepatic fibro-inflammation leads to progressive accumulation of collagen or fibrosis, increasing liver stiffness, and functional deterioration.
  • The predictive power of liver stiffness measurements on the course of disease is further enhanced when taken together with blood-based markers of liver disease.
  • Reduction in liver stiffness by rencofilstat likely indicates reduction in fibroinflammation, and reduction in risk for subsequent clinical outcome.